| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 26/09/2024 | 11:45 | PR Newswire (US) | Investors in Ardelyx, Inc. Should Contact The Gross Law Firm Before October 15, 2024 to Discuss Your Rights - ARDX | NASDAQ:ARDX | Ardelyx Inc |
| 23/09/2024 | 11:45 | PR Newswire (US) | ARDX LAWSUIT ALERT: The Gross Law Firm Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NASDAQ:ARDX | Ardelyx Inc |
| 19/09/2024 | 11:45 | PR Newswire (US) | The Gross Law Firm Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ARDX | NASDAQ:ARDX | Ardelyx Inc |
| 17/09/2024 | 00:14 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ARDX | Ardelyx Inc |
| 16/09/2024 | 11:45 | PR Newswire (US) | Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact The Gross Law Firm about pending Class Action - ARDX | NASDAQ:ARDX | Ardelyx Inc |
| 12/09/2024 | 11:45 | PR Newswire (US) | Ardelyx, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 15, 2024 to Discuss Your Rights - ARDX | NASDAQ:ARDX | Ardelyx Inc |
| 09/09/2024 | 11:45 | PR Newswire (US) | Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for Investors - Contact The Gross Law Firm | NASDAQ:ARDX | Ardelyx Inc |
| 05/09/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference | NASDAQ:ARDX | Ardelyx Inc |
| 26/08/2024 | 22:49 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ARDX | Ardelyx Inc |
| 26/08/2024 | 11:45 | PR Newswire (US) | Class Action Filed Against Ardelyx, Inc. (ARDX) - October 15, 2024 Deadline to Join - Contact The Gross Law Firm | NASDAQ:ARDX | Ardelyx Inc |
| 22/08/2024 | 11:45 | PR Newswire (US) | Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More | NASDAQ:ARDX | Ardelyx Inc |
| 17/08/2024 | 00:08 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ARDX | Ardelyx Inc |
| 12/08/2024 | 22:04 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARDX | Ardelyx Inc |
| 08/08/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer | NASDAQ:ARDX | Ardelyx Inc |
| 01/08/2024 | 22:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ARDX | Ardelyx Inc |
| 01/08/2024 | 22:01 | GlobeNewswire Inc. | Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update | NASDAQ:ARDX | Ardelyx Inc |
| 31/07/2024 | 14:02 | GlobeNewswire Inc. | Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion | NASDAQ:ARDX | Ardelyx Inc |
| 18/07/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024 | NASDAQ:ARDX | Ardelyx Inc |
| 17/07/2024 | 23:10 | GlobeNewswire Inc. | Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines | NASDAQ:ARDX | Ardelyx Inc |
| 02/07/2024 | 13:00 | GlobeNewswire Inc. | To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA | NASDAQ:ARDX | Ardelyx Inc |
| 28/06/2024 | 14:17 | GlobeNewswire Inc. | Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines | NASDAQ:ARDX | Ardelyx Inc |
| 04/06/2024 | 14:57 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:ARDX | Ardelyx Inc |
| 30/05/2024 | 22:02 | GlobeNewswire Inc. | Ardelyx, Inc. Reports Employment Inducement Grants | NASDAQ:ARDX | Ardelyx Inc |
| 22/05/2024 | 14:02 | GlobeNewswire Inc. | Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference | NASDAQ:ARDX | Ardelyx Inc |
| 21/05/2024 | 14:02 | GlobeNewswire Inc. | Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults | NASDAQ:ARDX | Ardelyx Inc |
| 16/05/2024 | 14:01 | GlobeNewswire Inc. | Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor) | NASDAQ:ARDX | Ardelyx Inc |
| 07/05/2024 | 14:01 | GlobeNewswire Inc. | Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference | NASDAQ:ARDX | Ardelyx Inc |
| 02/05/2024 | 22:02 | GlobeNewswire Inc. | Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update | NASDAQ:ARDX | Ardelyx Inc |
| 01/05/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings | NASDAQ:ARDX | Ardelyx Inc |
| 18/04/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024 | NASDAQ:ARDX | Ardelyx Inc |